M. Hutchinson

M. Hutchinson, 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity

M. Hutchinson, C. McGuigan, S. Hawkins, 2004, Journal of Neurology, Neurosurgery & Psychiatry.

The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical)

H. Kearney, M. Hutchinson, N. Tubridy, 2007, Journal of Neurology, Neurosurgery & Psychiatry.

A web-based electronic neurology referral system: a solution for an overburdened healthcare system?

M. Hutchinson, N. Tubridy, C. McGuigan, 2012, Irish medical journal.

Task-specific deactivation patterns in functional magnetic resonance imaging.

M Hutchinson, W Schiffer, S Joseffer, 1999, Magnetic resonance imaging.

Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials

David H. Miller, D. Arnold, A. Bar-Or, 2014, Annals of clinical and translational neurology.

David H. Miller, Deborah M. Miller, L. Kappos, 2007, Annals of neurology.

Chaos theory and the treatment of refractory status epilepticus: Who benefits from prolonged anesthesia, and is there a better way?

M. Hutchinson, P. Swanson, 2007, Medical hypotheses.

Cranial and peripheral neuropathy due to Epstein-Barr virus infection.

M. Hutchinson, Y. Langan, C. Gavin, 1997, Postgraduate medical journal.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level: Commentary

M. Hutchinson, 2015, Multiple sclerosis.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS

L. Kappos, C. Polman, S. Galetta, 2012, Journal of Neurology.

Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?

M. Hutchinson, N. Tubridy, R. Lonergan, 2009, Multiple sclerosis.

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

C. Polman, S. Galetta, F. Lublin, 2009, The Lancet Neurology.

Assessing disability progression with the Multiple Sclerosis Functional Composite

C. Polman, F. Lublin, Aaron E Miller, 2009, Multiple sclerosis.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

David H. Miller, D. Arnold, C. Pozzilli, 2016, Multiple sclerosis.

The prevalence of “pure” autosomal dominant hereditary spastic paraparesis in the island of Ireland

M. Hutchinson, S. Webb, P. Mcmonagle, 2002, Journal of neurology, neurosurgery, and psychiatry.

Phenotype of AD-HSP due to mutations in the SPAST gene

M Hutchinson, M. Hutchinson, S. Webb, 2000, Neurology.

Linkage to a known gene but no mutation identified: comprehensive reanalysis of SPG4 HSP pedigrees reveals large deletions as the sole cause

M. Pericak-Vance, A. Ashley-Koch, M. Hutchinson, 2007, Human mutation.

Detection of Parkinson's disease by MRI: Spin‐lattice distribution imaging

Michael Hutchinson, Ulrich Raff, M. Hutchinson, 2008, Movement disorders : official journal of the Movement Disorder Society.

Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia

M. Hutchinson, P. Byrne, P. Mcmonagle, 2004, Neurology.

M Hutchinson, M. Hutchinson, S. Webb, 2000, Neurology.

Linkage of AD HSP and cognitive impairment to chromosome 2p: haplotype and phenotype analysis indicates variable expression and low or delayed penetrance

M. Hutchinson, T. Burke, S. Webb, 1998, European Journal of Human Genetics.

Dementia in SPG4 hereditary spastic paraplegia

M. Hutchinson, P. Byrne, K. Kinsella, 2009, Neurology.

neuropathologic evidence Dementia in SPG4 hereditary spastic paraplegia: Clinical, genetic, and

M. Hutchinson, P. Byrne, K. Kinsella, 2010 .

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

L. Kappos, C. Polman, P. Calabresi, 2007, Neurology.

Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients.

Alexander V. Favorov, M. Hutchinson, M. Ochs, 2009, Pharmacogenomics.

Dystonia Management: What to Expect From the Future? The Perspectives of Patients and Clinicians Within DystoniaNet Europe

R. Reilly, M. Edwards, A. Albanese, 2021, Frontiers in Neurology.

Neuropsychological assessment in multiple sclerosis: methodological issues and concerns

M. Hutchinson, T. Burke, J. Hutchinson, 1996, Multiple sclerosis.

Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study

M. Hutchinson, N. Tubridy, C. McGuigan, 2020, Journal of sleep research.

Clinical Efficacy of BG-12 in Relapsing-Remitting Multiple Sclerosis (RRMS): Data from the Phase 3 CONFIRM Study (S01.003)

M. Hutchinson, E. Havrdová, Minhua Yang, 2012 .

Neurodegeneration in multiple sclerosis is a process separate from inflammation: No

M. Hutchinson, 2015, Multiple sclerosis.

Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities.

Nick C Fox, M. Rossor, J. Collinge, 2002, Neurology.

Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease

M. Hutchinson, A. Thompson, N. Tubridy, 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

CSF myelin basic protein in multiple sclerosis

M. Hutchinson, E. Martin, C. Feighery, 1985, Acta neurologica Scandinavica.

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

D. Aarsland, M. Hutchinson, J. Larsen, 2003, International journal of geriatric psychiatry.

Trials of Novel Therapies Specifically for Progressive MS

T. Friede, M. Hutchinson, R. Nicholas, 2018 .

Perceived and objective cognitive impairment in newly diagnosed versus established multiple sclerosis: impact of disease duration

M. Hutchinson, N. Tubridy, C. McGuigan, 2020, Irish Journal of Medical Science (1971 -).

The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosis.

P. Vermersch, M. Hutchinson, K. Evans, 2019, Multiple sclerosis and related disorders.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

L. Kappos, C. Polman, P. Calabresi, 2009, Journal of Neurology.

Effects of vitamin D3 in clinically isolated syndrome and healthy control participants: A double-blind randomised controlled trial

M. Hutchinson, N. Tubridy, C. Walsh, 2017, Multiple sclerosis journal - experimental, translational and clinical.

THE EFFECT OF STABILITY OF ORAL ANTICOAGULANT THERAPY UPON PATIENT‐PERCEIVED HEALTH STATUS AND QUALITY OF LIFE

M. Hutchinson, F. Kamali, H. Wynne, 2003, Journal of the American Geriatrics Society.

Inversion recovery MRI in idiopathic Parkinson disease is a very sensitive tool to assess neurodegeneration in the substantia nigra: preliminary investigation.

M. Hutchinson, U. Raff, I. Huete, 2006, Academic radiology.

Computer assessment of neurodegeneration in Parkinson disease using data fusion techniques with MR images.

Michael Hutchinson, Gonzalo M Rojas, Ulrich Raff, 2003, Academic radiology.

Bilateral paramedian thalamic infarction: a distinct but poorly recognized stroke syndrome.

M. Hutchinson, E. Martin, J. Stack, 1992, The Quarterly journal of medicine.

Amnesic syndrome after theophylline associated seizures: iatrogenic brain injury.

M. Hutchinson, J. O'riordan, J. Hutchinson, 1994, Journal of neurology, neurosurgery, and psychiatry.

Segmentation analysis in functional MRI: Activation sensitivity and gray‐matter specificity of RARE and FLASH

G. Johnson, D. Feinberg, H. Rusinek, 1997, Journal of magnetic resonance imaging : JMRI.

Psychosis and multiple sclerosis

M. Hutchinson, P. Buckley, 1993, British Journal of Psychiatry.

Preliminary evidence for correlation between PASAT performance and P3a and P3b amplitudes in progressive multiple sclerosis

R. Whelan, M. Hutchinson, N. Tubridy, 2011, European journal of neurology.

New versus old: Implications of evolving diagnostic criteria for relapsing–remitting multiple sclerosis

M. Hutchinson, N. Tubridy, K. O'Connell, 2019, Multiple sclerosis.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

J. Lechner-Scott, O. Pearson, M. Slee, 2017, The Lancet Neurology.

A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

L. Kappos, C. Polman, M. Hutchinson, 2016, Multiple sclerosis.

New perspectives in the natural history of multiple sclerosis

Michael Hutchinson, Helen Tremlett, Yinshan Zhao, 2010, Neurology.

Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study

M. Hutchinson, E. Havrdová, S. Sheikh, 2014, Multiple sclerosis.

Interferon-β1b in the treatment of secondary progressive MS

C. Pozzilli, C. Polman, R. Fitzpatrick, 2001, Neurology.

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

C. Pozzilli, L. Kappos, C. Polman, 2001, Neurology.

Natalizumab: A new treatment for relapsing remitting multiple sclerosis

M. Hutchinson, 2007, Therapeutics and clinical risk management.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

L. Kappos, C. Polman, P. Calabresi, 2009, Journal of Neurology.

New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin

M. Hutchinson, A. Vincent, M. Marnane, 2008, Journal of Neurology.

Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra

M Hutchinson, U Raff, M. Hutchinson, 1999, Journal of neurology, neurosurgery, and psychiatry.

Plantar power: reproducibility of the plantar response.

M. Hutchinson, L. Daly, J. Maher, 1992, BMJ.

Effects of BG-12 on Magnetic Resonance Imaging (MRI) Endpoints in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS): Data From the Phase 3 CONFIRM Study (S11.001)

D. Miller, M. Hutchinson, E. Havrdová, 2012 .

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Alexander Parajeles Vindas, P. Kowey, D. Arnold, 2016, Neurology. Clinical practice.

Predicting and preventing the future: actively managing multiple sclerosis

M. Hutchinson, 2009, Practical Neurology.

A proposed modification to the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis

M. Hutchinson, N. Tubridy, K. Kinsella, 2013, Multiple sclerosis.

A 10-year follow-up of the European multicenter trial of interferon β1 b in secondary-progressive multiple sclerosis

C. Polman, M. Hutchinson, B. Brochet, 2016 .

Unrecognised symptoms of depression in a community–based population with multiple sclerosis

M. Hutchinson, C. McGuigan, 2006, Journal of Neurology.

The efficacy of natalizumab on magnetic resonance imaging (MRI) measures in patients with relapsing multiple sclerosis (MS): Results from the AFFIRM trial

L. Kappos, C. Polman, F. Lublin, 2005 .

The longitudinal relationship between the patient-reported Multiple Sclerosis Impact Scale and the clinician-assessed Multiple Sclerosis Functional Composite

M. Hutchinson, N. Tubridy, C. Walsh, 2008, Multiple sclerosis.

Quantitation of T2 lesion load in patients with multiple sclerosis: a novel semiautomated segmentation technique.

M Hutchinson, G M Rojas, J H Simon, 2000, Academic radiology.

A clinical and laboratory study of benign multiple sclerosis.

A. Thompson, M. Hutchinson, E. Martin, 1986, The Quarterly journal of medicine.

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.

M. Hutchinson, R. Gold, E. Havrdová, 2014, Multiple sclerosis and related disorders.

Integrated multidisciplinary clinics should be the gold standard in managing progressive MS – Commentary

M. Hutchinson, 2016, Multiple sclerosis.

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study

M. Hutchinson, E. Havrdová, K. Dawson, 2013, Journal of Neurology.

Trials of Licenced RRMS DMTs in Progressive MS

M. Hutchinson, D. Hunt, 2018 .

Oral BG-12 (dimethyl fumarate) for relapsing–remitting multiple sclerosis: a review of DEFINE and CONFIRM

M. Hutchinson, R. Gold, E. Havrdová, 2013, Expert opinion on pharmacotherapy.

Spinal cord MRI should always be performed in clinically isolated syndrome patients: Commentary

M. Hutchinson, 2014, Multiple sclerosis.

Treatment adherence: what is the best that can be achieved?

M. Hutchinson, 2005, International MS journal.

Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

Viglietta, D. Miller, M. Hutchinson, 2012 .

Effect of BG-12 in subgroups of patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM (comparator and an oral fumarate in relapsing-remitting multiple sclerosis) study

Viglietta, D. Miller, M. Hutchinson, 2012 .

Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course.

A. Thompson, M. Hutchinson, E. Martin, 1985, Journal of neurology, neurosurgery, and psychiatry.

Suspected andclinically definite multiple sclerosis: therelationship between CSFimmunoglobulins and clinical course

M. Hutchinson, E. Martin, C. Feighery, 1985 .

Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

M. Hutchinson, E. Havrdová, C. Hotermans, 2014, European journal of neurology.

Unmet needs of multiple sclerosis patients in the community.

M. Hutchinson, N. Tubridy, R. Lonergan, 2015, Multiple sclerosis and related disorders.

The functional limitations profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis

M. Hutchinson, J. Hutchinson, 1995, Journal of Neurology.

Cognitive impairment in families with pure autosomal dominant hereditary spastic paraparesis.

M. Hutchinson, S. Webb, 1998, Brain : a journal of neurology.

The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study

L. Kappos, C. Polman, D. Miller, 2006 .

Intravenous therapy for the treatment of multiple sclerosis

M. Hutchinson, K. Nichol, J. Spicer, 2008 .

Do not treat from CIS onset: evaluate disease course and prognosis first - Commentary

M. Hutchinson, 2012, Multiple sclerosis.

OPL100 The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MS

Wynn, L. Kappos, C. Polman, 2005, Journal of the Neurological Sciences.

Economic costs associated with an MS relapse.

M. Hutchinson, N. Tubridy, S. Kelly, 2014, Multiple sclerosis and related disorders.

MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary

M. Hutchinson, 2014, Multiple sclerosis.

Three possible laboratory indexes of disease activity in multiple sclerosis

M. Hutchinson, C. Feighery, J. Brazil, 1987, Neurology.

Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies.

A. Thompson, M. Hutchinson, E. Martin, 1985, Journal of neurology, neurosurgery, and psychiatry.

Five-Year Follow-up of Delayed-Release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies (P7.234)

L. Kappos, A. Bar-Or, M. Hutchinson, 2015 .

Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12)

M Hutchinson, C McGuigan, M. Hutchinson, 2004, Neurology.

multiple sclerosis : findings from the CONFIRM study remitting − Effects of BG-12 ( dimethyl fumarate ) on health-related quality of life in patients with relapsing

M. Hutchinson, E. Havrdová, S. Sheikh, 2013 .

The Face-Symbol Test and the Symbol-Digit Test are not reliable surrogates for the Paced Auditory Serial Addition Test in multiple sclerosis

M. Hutchinson, N. Tubridy, K. O’Rourke, 2006, Multiple sclerosis.

In assessing multiple sclerosis disease activity patient report measures are a waste of time: cut to the MRI scan! – Commentary

M. Hutchinson, 2012, Multiple sclerosis.

NEUROIMAGING OF MOVEMENT DISORDERS

M. Hutchinson, 2008 .

Ascorbic acid for treatment in CMT1A: what's next?

M. Hutchinson, 2011 .

Marta Elian: Obituary

M. Hutchinson, 2017, Multiple sclerosis.

GDNF in treatment of Parkinson's disease: response to editorial

R. Penn, M. Hutchinson, B. Young, 2006, The Lancet Neurology.

Effect of a multidisciplinary clinic on survival in amyotrophic lateral sclerosis.

M. Hutchinson, T. Lynch, J. Redmond, 2004, Journal of neurology, neurosurgery, and psychiatry.

Multiparity in women with multiple sclerosis causes less long-term disability: Commentary

M. Hutchinson, 2014, Multiple sclerosis.

MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM)

Michael Hutchinson, Sergey Lebedev, Ulrich Raff, 2003, NeuroImage.

If I had CIS with MRI diagnostic of MS, I would take vitamin D 10,000 IU daily: Commentary

M. Hutchinson, 2013, Multiple sclerosis.

One can prevent post-partum MS relapses by exclusive breast feeding: Commentary

M. Hutchinson, 2013, Multiple sclerosis.

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

D. Aarsland, M. Hutchinson, J. Larsen, 2003, International journal of geriatric psychiatry.

The incidence of sudden unexpected death in epilepsy (sudep) in south dublin and wicklow

M. Hutchinson, Y. Langan, Y. Langan, 1998, Seizure.

Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS

M. Trojano, S. Vukusic, M. Hutchinson, 2019, Multiple sclerosis.

Late responses as aids to diagnosis in peripheral neuropathy.

M. Hutchinson, L. Daly, 1986, Journal of neurology, neurosurgery, and psychiatry.

The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Commentary

M. Hutchinson, 2012, Multiple sclerosis.

multiple sclerosis: Commentary MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in

M. Hutchinson, 2014 .

Symptom overlap in anxiety and multiple sclerosis

R. Reilly, R. Whelan, M. Hutchinson, 2013, Multiple sclerosis.

Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?

M. Hutchinson, C. Doherty, J. O'riordan, 1995, The Journal of urology.

Contrast sensitivity in multiple sclerosis measured by Cambridge Low Contrast Gratings: a useful clinical test?

M. Hutchinson, D. Glynn, J. Fahy, 1989, Journal of Neurology Neurosurgery & Psychiatry.

Visual evoked responses and immunoglobulin abnormalities in the diagnosis of multiple sclerosis

M. Hutchinson, E. Martin, C. Feighery, 1983, Acta neurologica Scandinavica.

Rehabilitation therapy in MS: a short-term, expensive, placebo: Commentary

M. Hutchinson, 2012, Multiple Sclerosis.

Ireland hereditary spastic paraparesis in the island of The prevalence of ' ' pure ' ' autosomal dominant

M. Hutchinson, S. Webb, P. Monagle, 2001 .

The frequent occurrence of neurological disease in patients with late-onset systemic lupus erythematosus.

B. Bresnihan, M. Hutchinson, K. McDonald, 1984, British journal of rheumatology.

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

S. Reingold, M. Filippi, X. Montalban, 2011, Annals of Neurology.

REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31.

M. Pericak-Vance, H. Smeets, S. Züchner, 2008, Brain : a journal of neurology.

M. Hutchinson, E. Havrdová, R. Fox, 2014, Current medical research and opinion.

Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

J. Lechner-Scott, O. Pearson, M. Slee, 2019, JAMA.

Advanced neuroimaging methods in the study of movement disorders: dystonia and blepharospasm.

J. Mazziotta, R. Woods, M. Hutchinson, 1998, Advances in neurology.

A high-density ERP study reveals latency, amplitude, and topographical differences in multiple sclerosis patients versus controls

H. Nolan, R. Lonergan, R. Whelan, 2010, Clinical Neurophysiology.

Using atypical symptoms and red flags to identify non-demyelinating disease

M. Hutchinson, N. Tubridy, C. Walsh, 2011, Journal of Neurology, Neurosurgery & Psychiatry.

Predicting and preventing the future: actively managing multiple sclerosis

M. Hutchinson, 2009, Practical Neurology.

Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome.

A. Durr, M. Hutchinson, S. Hanein, 2008, American journal of human genetics.

Hemichorea, moya‐moya, and ulcerative colitis

M. Hutchinson, P. Shanahan, D. O. Donoghue, 2001, Movement disorders : official journal of the Movement Disorder Society.

Title: a High-density Erp Study Reveals Latency, Amplitude, and Topographical Reilly (ebiomed: Ehealthcare Based on Biomedical Signal Processing and Ict for Integrated Diagnosis and Treatment of Disease)

R. Whelan, M. Hutchinson, N. Tubridy, 2010 .

Neurodegeneration in multiple sclerosis is a process separate from inflammation: No

M. Hutchinson, 2015, Multiple sclerosis.

Epstein-Barr virus is a necessary causative agent in the pathogenesis of multiple sclerosis: Commentary

M. Hutchinson, 2013, Multiple sclerosis.

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.

M. Hutchinson, E. Havrdová, M. Sweetser, 2012, New England Journal of Medicine.

Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: Experiences of an international panel.

M. Hutchinson, R. Gold, E. Havrdová, 2014, Multiple sclerosis and related disorders.

In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: Commentary

M. Hutchinson, 2013, Multiple sclerosis.